期刊
CELL
卷 183, 期 2, 页码 301-302出版社
CELL PRESS
DOI: 10.1016/j.cell.2020.09.053
关键词
-
资金
- NCI NIH HHS [P50 CA062924] Funding Source: Medline
Ott et al. report the results of a phase 1B study in which a personalized neoantigen vaccine was combined with programmed death receptor-1 blockade in patients with advanced cancers. The study provides a framework for combinatorial vaccine therapies that could mount robust T cell responses, enhance tumor killing, and provide clinical benefit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据